Catalyst Event
Viatris Inc (VTRS) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
Viatris outlined its long-term financial targets through 2030 at its Investor Day on March 19, 2026, where the company forecasts a 5-6% compound annual growth rate (CAGR) in total revenues and a 9-10% CAGR in adjusted EPS, forecasted. This is estimated to have a medium impact as long-term targets provide significant investor guidance.
Korean Translation
바이아트리스, 2026년 3월 19일 투자자의 날 행사에서 2030년까지의 장기 재무 목표를 발표했으며, 사측은 총 매출에서 5-6%의 연평균 성장률(CAGR)과 조정 주당 순이익에서 9-10%의 연평균 성장률을 전망함. 장기 목표 제시가 투자자에게 중요한 지표가 되므로 중간 정도의 영향이 예상됨.
Related Recent Events
Ionis Pharmaceuticals Inc (IONS) · Other
FDA target action (PDUFA) date for olezarsen for the treatment of severe hypertriglyceridemia (sHTG) following acceptance of sNDA for Priority Review. This is a major potential approval for a broad patient population, scheduled.
6/30/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Q1 2026 earnings release (Low impact estimated as routine earnings releases typically see at least 1% volatility) scheduled.
5/6/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol-Myers Squibb is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its first quarter 2026 financial results and host a conference call on April 29, 2026; importance is estimated at Medium as earnings reports typically drive significant price volatility, expected.
4/29/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
First quarter 2026 earnings results are scheduled to be released on April 23, 2026. This is expected to have a low impact as a routine financial update, scheduled.
4/23/2026, 12:00:00 AM